Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy

Jessica Katharine Dyson, Mark Hudson and Stuart McPherson
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.14-5-551
Clin Med October 2014
Jessica Katharine Dyson
AFreeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Roles: clinical hepatology fellow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jessicadyson@doctors.org.uk
Mark Hudson
BFreeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Roles: consultant hepatologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart McPherson
CFreeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Roles: consultant hepatologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

ABSTRACT

Patients with current or past hepatitis B virus (HBV) infection are at risk of viral reactivation if they receive immune-modulating treatment or chemotherapy. This can range from subclinical elevation in HBV DNA levels, to abnormal liver function tests, to severe hepatitis with liver failure and risk of death. All patients should be screened for hepatitis B with surface antigen and core antibody before receiving immunosuppression. Patients with positive hepatitis B serology should be referred for specialist advice. Prophylactic antiviral treatment is recommended for patients with current/past hepatitis B who receive immunosuppressive chemotherapy.

KEYWORDS:
  • Hepatitis B
  • reactivation
  • immunosuppression
  • chemotherapy
  • antiviral therapy.

Introduction

Patients with current or past hepatitis B virus (HBV) infection are at risk of viral reactivation if they receive immune-modulating treatment or chemotherapy. This can range from subclinical elevation in HBV DNA levels to abnormal liver function tests (LFTs), to severe hepatitis with liver failure and risk of death.

Case report

A 72-year-old man was noted to have submandibular gland swelling at a dental appointment. Further assessment showed widespread lymphadenopathy and excision biopsy diagnosed diffuse large B-cell lymphoma. His past medical history included pulmonary embolus.

He was planned for six cycles of R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin [hydroxydaunomycin], vincristine, prednisolone). Before starting treatment, hepatitis B serology was checked; he was anti-HBcAb (hepatitis B core antibody) positive, HBsAg (hepatitis B surface antigen) negative, anti-HBsAb (hepatitis B surface antibody) negative with undetectable HBV DNA (<20 IU/ml), in keeping with past HBV infection. LFTs were normal. The virology report stated: ‘consistent with past HBV infection, but risk of reactivation on immunosuppression. Please ensure HBsAg and LFTs are monitored.’

After four cycles of R-CHOP (January 2013), tests for HBsAg were positive and HBV DNA was 1.2’ 107 IU/ml, consistent with acute HBV reactivation. The patient was started on tenofovir 245 mg daily.

He completed six cycles in March 2013 and positron emission tomography computed tomography (PET-CT) confirmed good radiological response. However, in May 2013 he was admitted with jaundice and international normalised ratio (INR) >10. Blood tests showed significant liver dysfunction (bilirubin 105 μmol/l, alanine aminotransferase [ALT] 988 U/l, alkaline phosphatase [ALP] 317 U/l and albumin 35 g/l). HBV DNA had fallen to 5,300 IU/ml. An abdominal CT scan showed no biliary obstruction or other cause for jaundice. Tests for other hepatotrophic viruses were negative. Transjugular liver biopsy showed markedly cholestatic hepatitis (modified histology activity index [HAI] inflammatory grade 9/18 and fibrosis stage 5/6), in keeping with fibrosing cholestatic hepatitis B (Fig 1). He was started on lamivudine in addition to tenofovir, but his clinical condition deteriorated (bilirubin 366 μmol/l, albumin 31 g/l). He required prolonged hospital admission (3 weeks) complicated by poor nutrition and pruritis. Fig 2 shows a graph of his blood tests during the HBV reactivation. His LFTs gradually improved and normalised after 5 months. He is now clinically well and remains on tenofovir.

Key points

  • Patients with current or past hepatitis B (HBV) infection are at risk of viral reactivation if they receive immune-modulating treatment or chemotherapy

  • Reactivation can range from subclinical elevation in HBV DNA levels, to severe hepatitis with liver failure and death

  • All patients should be screened for hepatitis B with surface antigen and core antibody before receiving immunosuppression

  • Patients with positive hepatitis B serology should be referred for specialist advice

  • Prophylactic antiviral treatment is recommended for patients with current/past hepatitis B who receive immunosuppressive chemotherapy

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Liver biopsy showing markedly cholestatic hepatitis (modified histology activity index [HAI] inflammatory grade 9/18 and fibrosis stage 5/6) in keeping with fibrosing cholestatic hepatitis B.

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Patient's blood results during the hepatitis B virus (HBV) reactivation. (a) Bilirubin and (b) alanine aminotransferase (ALT). HBcAb = hepatitis B core antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; R-CHOP = rituximab, cyclophosphamide, doxorubicin [hydroxydaunomycin], vincristine, prednisolone.

Discussion

The use of rituximab (and other immunosuppressants) is increasing for various autoimmune, haematological and oncological conditions. The purpose of presenting this case is to raise awareness of this potentially life-threatening complication for clinicians who prescribe rituximab and other immunosuppressants. Due to the risk of HBV reactivation with immunosuppression, international guidelines recommend screening all patients for HBsAg and anti-HBcAb before initiating treatment to identify ‘at-risk’ patients1,2 who can be actively monitored or given prophylaxis. Despite these recommendations, HBV screening remains sporadic, with one large US series showing that only 16% of 18,688 patients were screened before chemotherapy.3 Studies assessing HBV screening practices of oncologists suggest that 20–47% of oncologists do not routinely screen for HBV before treatment, 20% never screen and others screen ‘high-risk’ individuals.4,5 Zurawska et al6 developed a decision model to compare clinical outcomes, costs and cost-effectiveness of three HBV screening strategies for patients receiving R-CHOP. Screening all patients was the least costly and associated with the highest 1-year survival rate (compared with screening ‘high risk’ and ‘none’). Worldwide, chronic HBV infection is very common7 and importantly a high proportion of patients with current or past HBV infection are unaware of the infection,8 so it is important to screen all patients who receive immunosuppression/chemotherapy.9

In this case, HBV screening was undertaken before starting R-CHOP and the patient was anti-HbcAb positive, but HBsAg negative, in keeping with past infection. The decision was made to monitor for reactivation with LFTs, HBsAg and HBV DNA testing during chemotherapy, as per the guidelines of the European Association of the Study of the Liver (EASL). After 3 months, blood tests showed HBsAg positivity and high HBV DNA, suggesting active HBV. Patients who have had past HBV infection can reactivate because covalently closed, circular HBV DNA (cccDNA) is archived in hepatocyte nuclei and remains under immune control,10 although in states of immunosuppression viral replication can occur, leading to production of HBV DNA and HBsAg and subsequent HBV reactivation.

When this patient showed serological evidence of HBV reactivation he was treated with tenofovir to suppress viral replication, but 2 months later, after chemotherapy was complete, he developed a very severe fibrosing cholestatic hepatitis. Importantly, the consequences of HBV reactivation (severe hepatitis) frequently occur after completion of chemotherapy when immune reconstitution occurs and the cytotoxic T-cell-mediated response is restored.11 HBV reactivation can occur anywhere from 2 weeks to more than 1 year after cessation of immunosuppression.9 Therefore, ongoing monitoring of patients is essential after chemotherapy, even if they are started on antiviral therapy.

There are many immunosuppressive and chemotherapeutic agents and the absolute risk of HBV reactivation varies with specific regimens,9,11 although few studies have assessed risks with specific agents. Overall, studies suggest a reactivation rate of approximately 50% for HBsAg-positive patients receiving chemotherapy for lymphoma and 15% for solid tumours.12–16 Patients with past infection (anti-HBcAb positive only) have lower reactivation rates (approximately 5%).17,18 More intensive immunosuppressive regimens, particularly those including rituximab and/or high-dose steroids, are the highest risk.9,11 Recent studies suggest that reactivation rates in anti-HBcAb-positive patients treated with rituximab are 25%.19,20 The clinical significance of HBV reactivation can be variable, ranging from a mild transaminitis to liver failure and death. Severe reactivation resulting in jaundice occurs in 10–22% of patients and has a high mortality rate of 4–41%.12,13,15,21,22 As well as being a life-threatening complication, the medical resource costs of HBV reactivation can be significant, as in this case.

Importantly, HBV reactivation in HBsAg- or anti-HBcAb-positive patients can be prevented by prophylactic treatment with oral antiviral drugs.23,24 Studies have shown that prophylactic antiviral therapy before starting immunosuppression is more effective at preventing hepatitis and reduces mortality compared with initiating treatment once reactivation has occurred.23,24 As a result, EASL and the National Institute for Health and Care Excellence (NICE) guidance advises prophylactic antiviral therapy for all HBsAg-positive patients who undergo treatment with immunosuppression or chemotherapy,2 and treatment should be continued for at least 6 months after completion of immunosuppressive therapy.25 NICE guidelines (Fig 3) recommend treatment with lamivudine if HBV DNA is <2,000 IU/ml and the immunosuppression/chemotherapy will last <6 months.26 For patients whose HBV DNA is >2,000 IU/ml, or who will receive immunosuppression/chemotherapy for >6 months, entecavir or tenofovir treatment is recommended.

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

Recommendations of the National Institute for Health and Care Excellence (2013) for the management of hepatitis B in patients receiving immunosuppression and chemotherapy. ALT = alanine aminotransferase; CHB = chronic hepatitis B; Anti-HBc = hepatitis B core antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; Anti-HBs = hepatitis B surface antibody.

For anti-HBcAb-positive/HBsAg-negative patients receiving immunosuppression/chemotherapy, EASL guidelines recommend ALT and HBV DNA monitoring 1- to 3-monthly and antiviral therapy to be started if the HBV DNA increases.2 Our patient was managed according to these recommendations. However, in view of increasing evidence of the high risk of reactivation in anti-HBcAb-positive patients with rituximab, the new NICE guidelines that were published after this patient presented recommend prophylactic treatment with lamivudine.25 If our patient had been managed according to these guidelines his reactivation might have been prevented. For anti-HBcAb-positive patients who receive immunosuppressive regimens without rituximab, NICE guidelines recommend monitoring HBV DNA levels monthly and treating with antivirals if HBV DNA increases.25

Conclusion

This case highlights the importance of HBV testing in patients receiving immunosuppression or chemotherapy to identify patients at risk of HBV reactivation, and to treat patients who have current or past HBV infection prophylactically with antiviral therapy to prevent reactivation and the associated morbidity and mortality.

  • © 2014 Royal College of Physicians

References

  1. 1.↵
    1. Weinbaum CM,
    2. Williams I,
    3. Mast EE,
    4. et al.
    Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR CDC 2008;57(RR-8):1–20.
    OpenUrl
  2. 2.↵
    1. European Association for the Study of the Liver
    . EASL clinical -practice guidelines: Management of chronic hepatitis B virus -infection. J Hepatol 2012;57:167–85.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Hwang JP,
    2. Fisch MJ,
    3. Lok AS,
    4. et al.
    Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534.doi:10.1186/1471-2407-13-534
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Day FL,
    2. Link E,
    3. Thursky K,
    4. et al.
    Current hepatitis B screening -practices and clinical experience of reactivation in patients -undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011;7:141–7.doi:10.1200/JOP.2010.000133
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Tran TT,
    2. Rakoski MO,
    3. Martin P,
    4. et al.
    Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Therapeut 2010;31:240–6.
    OpenUrlPubMed
  6. 6.↵
    1. Zurawska U,
    2. Hicks LK,
    3. Woo G,
    4. et al.
    Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012;30:3167–73.doi:10.1200/JCO.2011.40.7510
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Cooke GS,
    2. Main J,
    3. Thursz MR
    . Treatment for hepatitis B. BMJ 2010;340:b5429.doi:10.1136/bmj.b5429
    OpenUrlFREE Full Text
  8. 8.↵
    1. McPherson S,
    2. Valappil M,
    3. Moses SE,
    4. et al.
    Targeted case finding for hepatitis B using dry blood spot testing in the British–Chinese and South Asian populations of the North-East of England. J Viral Hepatitis 2013;20:638–44.doi:10.1111/jvh.12084
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Hwang JP,
    2. Vierling JM,
    3. Zelenetz AD,
    4. et al.
    Hepatitis B virus -management to prevent reactivation after chemotherapy: a review. Support Care Cancer 2012;20:2999–3008.doi:10.1007/s00520-012-1576-7
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Rehermann B,
    2. Ferrari C,
    3. Pasquinelli C,
    4. et al.
    The hepatitis B virus persists for decades after patients’ recovery from acute viral -hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med 1996;2:1104–8.doi:10.1038/nm1096-1104
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Wursthorn K,
    2. Wedemeyer H,
    3. Manns MP
    . Managing HBV in patients with impaired immunity. Gut 2010;59:1430–45.doi:10.1136/gut.2009.195834
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Lok AS,
    2. Liang RH,
    3. Chiu EK,
    4. et al.
    Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a -prospective study. Gastroenterology 1991;100:182–8.
    OpenUrlPubMed
  13. 13.↵
    1. Markovic S,
    2. Drozina G,
    3. Vovk M,
    4. et al.
    Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepato-gastroenterology 1999;46:2925–30.
    OpenUrlPubMed
  14. 14.↵
    1. Nakamura Y,
    2. Motokura T,
    3. Fujita A,
    4. et al.
    Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic -malignancies. Survey in Japan, 1987–1991. Cancer 1996;78:2210–15.doi:10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Kumagai K,
    2. Takagi T,
    3. Nakamura S,
    4. et al.
    Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl 1):107–9.doi:10.1023/A:1008234807768
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Yeo W,
    2. Chan PK,
    3. Zhong S,
    4. et al.
    Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk -factors. J Med Virol 2000;62:299–307.doi:10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Uhm JE,
    2. Kim K,
    3. Lim TK,
    4. et al.
    Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell -transplantation. Biol Blood Marrow Transplant 2007;13:463–8.doi:10.1016/j.bbmt.2006.11.019
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hui CK,
    2. Cheung WW,
    3. Zhang HY,
    4. et al.
    Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients -undergoing -cytotoxic chemotherapy. Gastroenterology 2006;131:59–68.doi:10.1053/j.gastro.2006.04.015
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Yeo W,
    2. Chan TC,
    3. Leung NW,
    4. et al.
    Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605–11.doi:10.1200/JCO.2008.18.0182
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Huang YH,
    2. Hsiao LT,
    3. Hong YC,
    4. et al.
    Randomised controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013;31:2765–72.doi:10.1200/JCO.2012.48.5938
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Liang R
    . How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:3147–53.doi:10.1182/blood-2008-10-163493
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Hoofnagle JH,
    2. Dusheiko GM,
    3. Schafer DF,
    4. et al.
    Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447–9.doi:10.7326/0003-4819-96-4-447
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Hsu C,
    2. Hsiung CA,
    3. Su IJ,
    4. et al.
    A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomised trial. Hepatology 2008;47:844–53.doi:10.1002/hep.22106
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Loomba R,
    2. Rowley A,
    3. Wesley R,
    4. et al.
    Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during -chemotherapy. Ann Intern Med 2008;148:519–28.doi:10.7326/0003-4819-148-7-200804010-00008
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Sarri G,
    2. Westby M,
    3. Bermingham S,
    4. et al.
    Diagnosis and -management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ 2013;346:f3893.doi:10.1136/bmj.f3893
    OpenUrlFREE Full Text
  26. 26.↵
    1. National Institute for Health and Care Excellence
    . Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in -children, young people and adults. CG165. London: NICE, 2013. www.nice.org.uk/guidance/cg165 [Accessed 4 August 2014]
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy
Jessica Katharine Dyson, Mark Hudson, Stuart McPherson
Clinical Medicine Oct 2014, 14 (5) 551-555; DOI: 10.7861/clinmedicine.14-5-551

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy
Jessica Katharine Dyson, Mark Hudson, Stuart McPherson
Clinical Medicine Oct 2014, 14 (5) 551-555; DOI: 10.7861/clinmedicine.14-5-551
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Introduction
    • Case report
    • Discussion
    • Conclusion
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Lessons of the month: A challenging presentation of hypopituitarism secondary to an intracerebral aneurysm
  • Lessons of the month: ANCA-associated vasculitis – granulomatosis with polyangiitis: ‘the great mimic’
  • Lessons of the month: Acute liver failure: a case close to the heart
Show more Lessons of the month

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians